Tome Biosciences emerged from stealth with $213 million in financing and plans to create curative cell and gene therapies that correct genes in vivo. The company’s programmable genomic integration technology enables the insertion of any DNA sequence into any programmed genomic location. Initial projects include gene therapies for monogenic liver diseases and cell therapies for autoimmune diseases. The company, which has almost 150 employees, plans to disclose clinical indications for its first therapies in 2024.
Group-IB’s Threat Intelligence and Defence Centre Equip Undergraduates with Sophisticated Cybersecurity Technologies to Boost Threat Analysis and Enhance Cyber Resilience for Campus Start-ups
Hey there from the heart of the San Francisco Bay Area! It’s an absolute pleasure to have you back again for our chat on some
